CLDX FY 2023 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+192.0% YoY

Gross Profit

-$111M-1614.5% margin

Operating Income

-$155M-2245.3% margin

Net Income

-$141M-2054.8% margin

EPS (Diluted)

$-2.92

Cash Flow

Operating Cash Flow

-$107M

Free Cash Flow

-$109M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$466M

Total Liabilities

$36M

Stockholders' Equity

$429M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$2M	+192.0%
Gross Profit	-$111M	-$80M	-39.1%
Operating Income	-$155M	-$115M	-34.1%
Net Income	-$141M	-$112M	-25.9%